tirzepatide weight loss surmount-1 results percent weight loss 72 weeks reduction over time in tirzepatide‐treated participants by early response: Post hoc analysis in SURMOUNT‐1 - Ard - 2025 - Diabetes, Obesity and Metabolism Tirzepatide weight-loss study shows promising

Hypoglycemia rates remained low with both drugs

Its extended half-life allows for once-weekly research protocols, and ongoing investigation spans cardiometabolic health, hepatic fat metabolism, and sleep-disordered breathing

What are the clinical trial weight loss results for Mounjaro/Zepbound

Same-day approval without labs and a one-button cancellation process make it one of the easiest clinics to start with

Health conditions Certain health conditions make it harder to lose weight namely, and somewhat ironically, type 2 diabetes (T2D)

Improved Metabolic Health Both medications improve glucose control, which can benefit individuals with type 2 diabetes